Inflammatory pathways drive atherogenesis and link conventional risk factors to
atherosclerosis and its complications. One inflammatory mediator has come to the fore as a …

Recent clinical trials have now firmly established that inflammation participates causally in
human atherosclerosis. These observations point the way toward novel treatments that add …

Aims Targeting vascular inflammation represents a novel therapeutic approach to reduce
complications of atherosclerosis. Neutralizing the pro-inflammatory cytokine interleukin-1β …

Atherothrombosis is no longer considered solely a disorder of lipoprotein accumulation in
the arterial wall. Rather, the initiation and progression of atherosclerotic lesions is currently …

The role of inflammation in atherosclerosis has been recognized several decades ago and
existing treatments provide benefits in part through non-specific anti-inflammatory actions …

It has recently been appreciated that atherosclerosis is predominantly an inflammatory
process. Atherosclerosis begins with a fatty streak, which is made up almost entirely of …

Plasma levels of the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP)
predict vascular risk with an effect estimate as large as that of total or high-density …

The importance of inflammation as a driver of pathology is no longer confined to
autoimmune and infectious diseases. In line with convincing experimental data as well as …

IL (interleukin)-6 is a pivotal cytokine of innate immunity, which enacts a broad set of
physiological functions traditionally associated with host defense, immune cell regulation …

Atherosclerosis is considered to be a chronic inflammatory disease of the arterial wall.
Atherogenesis is accompanied by local production and release of inflammatory mediators …